Publication

The clinical impact and cost-effectiveness of measles-mumps-rubella vaccination to prevent measles importations among international travelers from the United States

Authored by:

Hyle EP, Fields NF, Fiebelkorn AP et al.

Full Citation:

Hyle EP, Fields NF, Fiebelkorn AP et al. 2018. The clinical impact and cost-effectiveness of measles-mumps-rubella vaccination to prevent measles importations among international travelers from the United States. Clinical Infectious Diseases. 69(2).

View Publication

Additional key concepts from this publication:

Importation of diseases across international borders are a threat to domestic disease control.

Key Evidence: Measles cases in the US continue to occur due to importation of the disease. In 2009-2014, 74% of US measles cases were among US residents returning from overseas. Vaccinating US travelers with MMR vaccine before traveling internationally would be cost-effective or even cost-saving for those traveling to measles “hot spots”, especially if the travelers were previously unvaccinated or returning to US communities with varying MMR coverage rates. However, it would not be cost-effective for all US persons traveling overseas given the large numbers of travelers.

Vaccines are among the most cost-effective health interventions available.